| |
 |
| Publications |
 |
Liposarcoma of thigh presenting as deep venous thrombosis
N K Singh* and R Kolluri* |
|
Dyslipidemia in South Asians living in a western
community
Raghu Kolluri, MD*, Daryl Pinedo, MD, Ardis Edmondson-Holt, PhD, Kanny S. Grewal, MD., James M. Falko, MD |
|
Heparin-Induced Thrombocytopenia
With Thrombosis After Endovascular
Aneurysm Repair
Raghu Kolluri, MD, Krishna Rocha-Singh, MD,
Timur Sarac, MD, and John R. Bartholomew, MD |
|
Internal mammary artery and inferior epigastric artery collateralization in a patient with aortoiliac occlusive disease
Raghu Kolluri, Richard Holloway and Gregory Mishkel |
|
Atherosclerotic Peripheral Vascular Disease Symposium II
Intervention for Renal Artery Disease
Krishna J. Rocha-Singh, MD, Chair; Andrew C. Eisenhauer, MD; Stephen C. Textor, MD, FAHA;
Christopher J. Cooper, MD, FAHA; Walter A. Tan, MS, MD;
Alan H. Matsumoto, MD; Kenneth Rosenfield, MD; for Writing Group 8 |
|
Rural Interhospital Transfer of ST-Elevation Myocardial Infarction Patients for Percutaneous Coronary Revascularization: The Stat Heart Program
Frank V. Aguirre, Joji J. Varghese, Michael P. Kelley, Wilfred Lam, Charles L. Lucore, John B. Gill, Lisa Page, Leah Turner, Conrad Davis and Frank L. Mikell |
|
Renal effects of contrast media in diabetic patients undergoing
diagnostic or interventional coronary angiography
Kathy J. Hardiek, Richard E. Katholi, Randall S. Robbs, Charles E. Katholi |
|
Stent Thrombosis Rates Increase Over Time
referencing Gregory J. Mishkel, MD |
|
Drug-Eluting Stent Thrombosis Rate
Suggests Acceleration Over Time
referencing Gregory J. Mishkel, MD |
|
Highlights of the Year in JACC 2007
referencing Gregory J. Mishkel, Anna L. Moore, Steve Markwell, M. Coleman Shelton, and Marc E. Shelton. |
|
Short- and Long-Term Clinical Outcomes of Coronary DrugEluting Stent Recipients Presenting with Chronic Renal Disease *
by Gregory J. Mishkel, MD, Joji J. Varghese, MD, Anna L. Moore, MPH, Frank Aguirre, MD, Stephen J. Markwell, MS, Marc Shelton, MD |
|
Long-Term Outcomes After Management of Restenosis or Thrombosis of Drug-Eluting Stents *
by Gregory J. Mishkel, Anna L. Moore, Steve Markwell, M. Coleman Shelton and Marc E. Shelton |
|
Bivalirudin versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Drug-Eluting Stent Implantations in the Absence of Acute Myocardial Infarction: Clinical and Economic Results *
by
Gregory J. Mishkel, MD, Anna L. Moore, MPH, Stephen J. Markwell, MA, and Robert W. Ligon, MS |
|
Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial *
by Mark A. Turco, John A. Ormiston, Jeffrey J. Popma, Lazar Mandinov, Charles D. O’Shaughnessy, Tift Mann, Thomas F. McGarry, Chiung-Jen Wu, Charles Chan, Mark W.I. Webster, Jack J. Hall, Gregory J. Mishkel, Louis A. Cannon, Donald S. Baim, and Joerg Koglin |
|
Contrast-induced Nephropathy -
Update and
Practical Clinical Applications *
by Richard E Katholi,MD |
|
Performance Goals and Endpoint Assessments for Clinical Trials of Femoropopliteal Bare Nitinol Stents in Patients With Symptomatic Peripheral Arterial Disease *
by Dr. Krishna J. Rocha-Singh |
| |
|
| |
*Adobe Reader required.
 |
|
|
|
|
